Skip to main
  1. Stocks
  2. ArriVent Biopharma Inc
  3. Forecast
AVBP

AVBP Stock Forecast & Price Target

AVBP Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ArriVent BioPharma is viewed favorably because its lead asset firmonertinib still has meaningful upside in EGFR PACC NSCLC, supported by strong Phase 1b data of 68% confirmed ORR, 16.0-month PFS, and 53% CNS ORR, while the ongoing global Phase 3 ALPACCA study could enable accelerated or full approval if results are positive. Its second major value driver is the ADC pipeline, especially ARR-217, whose first-in-human data showed 38% confirmed ORR at the 6 mg/kg RP2D, about 7.1-7.2 months mPFS, and a favorable safety profile, with additional dose-optimization and combination data in 1H27 and 2H27 that could broaden the opportunity into earlier-line colorectal and other GI cancers. The balance sheet also supports the thesis, with $393.2M in cash and investments expected to fund operations to mid-2028, giving the company enough runway to absorb the FURVENT setback while advancing multiple catalysts.

Bears say

ArriVent BioPharma is facing a major setback as the registrational global Ph 3 FURVENT study of firmonertinib in 1L EGFR exon20ins NSCLC failed to meet its primary PFS endpoint by BICR, undermining confidence in the company’s lead asset. Although the 240mg arm showed numerically better results, including 11.0 vs. 9.5 months mPFS, 60% vs. 33% cORR by BICR, and 11.1 vs. 7.1 months INV-assessed mPFS, the key BICR miss and discordance in the chemo control arm leave the clinical interpretation uncertain. With the company still reviewing the full dataset and not planning a firmonertinib update until 1Q27, the near-term catalyst profile looks weak and the exon20ins opportunity remains excluded from the model.

AVBP has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ArriVent Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

AVBP Analyst Forecast & Price Prediction

Get the latest AVBP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AVBP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ArriVent Biopharma Inc (AVBP) Forecast

Analysts have given AVBP a Strong Buy based on their latest research and market trends.

According to 8 analysts, AVBP has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ArriVent Biopharma Inc (AVBP)


AVBP Analyst Forecast & Price Prediction

Get the latest AVBP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AVBP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AVBP stock data and trends